ProfileGDS5678 / 1452833_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 92% 92% 95% 92% 94% 94% 92% 92% 93% 93% 93% 93% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9687493
GSM967853U87-EV human glioblastoma xenograft - Control 27.7835592
GSM967854U87-EV human glioblastoma xenograft - Control 37.7055992
GSM967855U87-EV human glioblastoma xenograft - Control 48.6491695
GSM967856U87-EV human glioblastoma xenograft - Control 57.739792
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.7843194
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9813494
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.6057192
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.539892
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8291793
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.814193
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9154993
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.7809893
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.6429692